
Quotient Therapeutics kicks-off with US$50m financing
Flagship has confírmed to invest $50m in Quotient Therapeutics to advance development of a platform, licenced from Wellcome Sanger Institue...

Amyl Therapeutics bags €11m Series A extension
Amyl Therapeutics SA has secured €5m Series A extension from long-term investors Merieux Equity Partners and Noshaq, together with Mr Evren Ucok as a...

Roche acquires Telavant Holdings to win TLA1 race
The takeover of Telavant, a 75:25 jont-venture of Roivant Sciences and the US pharmaceutical group Pfizer, however, may cost Roche up to US-$7.25bn....

BioLamina AB bags €19m funding for expansion
The tenth investement from Lauxera Capital Partners through its Lauxera Growth I fund will be usesd by the Swedish company to expand the development...

AMR: Partnership set to improve in vivo antibiotics testing
The development of novel antibiotics is crucial in the fight against antimicrobial resistance (AMR) but has been neglected for decades due to a lack...

Radiotherapy R&D partnership
French-US company Orano Med is developing Lead-212 (212Pb) Targeted Alpha Therapy, which combines the ability of biological molecules such as...

Unveiling prostate cancer's Achilles' heel
An international research team, including experts from IRB Barcelona, Max Planck Institute for Molecular Genetics, and BC Cancer, discovered a...